Posted by Michael Wonder on 25 Jun 2024
AbbVie provides US regulatory update on ABBV-951 (foscarbidopa/foslevodopa)
25 June 2024 - AbbVie continues to work with the FDA to bring ABBV-951 to patients in the US as quickly as possible.
AbbVie today announced it received a complete response letter from the US FDA for the new drug application for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson's disease.
